You can buy or sell PSTI and other stocks, options, ETFs, and crypto commission-free!
Pluristem Therapeutics, Inc. engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. Read More It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
52 Week High
52 Week Low
BRIEF-Pluristem Treated First Three Covid-19 Patients In Israel Under Compassionate Use
March 30 (Reuters) - Pluristem Therapeutics Inc: * PLURISTEM TREATED FIRST THREE COVID-19 PATIENTS IN ISRAEL UNDER COMPASSIONATE USE * PLURISTEM THERAPEUTICS
BRIEF-Pluristem Provides Update On COVID-19 Preparedness, Current Phase Iii Clinical Trials Status And Treatment Development Activity
March 26 (Reuters) - Pluristem Therapeutics Inc: * PLURISTEM PROVIDES UPDATE ON COVID-19: PREPAREDNESS, CURRENT PHASE III CLINICAL TRIALS STATUS AND TREATMENT
— per share
Expected May 4, After Hours